Top

Published in:

Open Access 01-09-2017 | Original Paper

Deferiprone Rescues Behavioral Deficits Induced by Mild Iron Exposure in a Mouse Model of Alpha-Synuclein Aggregation

Authors: Eleonora Carboni, Lars Tatenhorst, Lars Tönges, Elisabeth Barski, Vivian Dambeck, Mathias Bähr, Paul Lingor

Published in: NeuroMolecular Medicine | Issue 2-3/2017

Abstract

Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, and its causes remain unknown. A major hallmark of the disease is the increasing presence of aggregated alpha-synuclein (aSyn). Furthermore, there is a solid consensus on iron (Fe) accumulation in several regions of PD brains during disease progression. In our study, we focused on the interaction of Fe and aggregating aSyn in vivo in a transgenic mouse model overexpressing human aSyn bearing the A53T mutation (prnp.aSyn.A53T). We utilized a neonatal iron-feeding model to exacerbate the motor phenotype of the transgenic mouse model. Beginning from day 100, mice were treated with deferiprone (DFP), a ferric chelator that is able to cross the blood–brain barrier and is currently used in clinics as treatment for hemosiderosis. Our paradigm resulted in an impairment of the learning abilities in the rotarod task and the novel object recognition test. DFP treatment significantly improved the performance in both tasks. Although this was not accompanied by alterations in aSyn aggregation, our results support DFP as possible therapeutic option in PD.

Available only for authorised users

Abbruzzese, G., Cossu, G., Balocco, M., Marchese, R., Murgia, D., Melis, M., et al. (2011). A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica, 96(11), 1708–1711. doi:10.3324/haematol.2011.043018.CrossRefPubMedPubMedCentral

Angot, E., Steiner, J. A., Lema Tomé, C. M., Ekström, P., Mattsson, B., Björklund, A., et al. (2012). Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS ONE, 7(6), e39465. doi:10.1371/journal.pone.0039465.CrossRefPubMedPubMedCentral

Asano, T., Koike, M., Sakata, S. I., Takeda, Y., Nakagawa, T., Hatano, T., et al. (2015). Possible involvement of iron-induced oxidative insults in neurodegeneration. Neuroscience Letters, 588(1), 29–35. doi:10.1016/j.neulet.2014.12.052.CrossRefPubMed

Bareggi, S. R., & Cornelli, U. (2012). Clioquinol: Review of its mechanisms of action and clinical uses in neurodegenerative disorders. CNS Neuroscience & Therapeutics, 18(1), 41–46. doi:10.1111/j.1755-5949.2010.00231.x.CrossRef

Bevins, R. A., & Besheer, J. (2006). Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study “recognition memory”. Nature Protocols, 1(3), 1306–1311. doi:10.1038/nprot.2006.205.CrossRefPubMed

Billings, J. L., Hare, D. J., Nurjono, M., Volitakis, I., Cherny, R. A., Bush, A. I., et al. (2016). Effects of neonatal iron feeding and chronic clioquinol administration on the Parkinsonian human A53T transgenic mouse. ACS Chemical Neuroscience, 7(3), 360–366. doi:10.1021/acschemneuro.5b00305.CrossRefPubMed

Binolfi, A., Rasia, R. M., Bertoncini, C. W., Ceolin, M., Zweckstetter, M., Griesinger, C., et al. (2006). Interaction of alpha-synuclein with divalent metal ions reveals key differences: A link between structure, binding specificity and fibrillation enhancement 21. Journal of the American Chemical Society, 128(30), 9893–9901. doi:10.1021/ja0618649.CrossRefPubMed

Butler, D. A., Scott, M. R., Bockman, J. M., Borchelt, D. R., Taraboulos, A., Hsiao, K. K., et al. (1988). Scrapie-infected murine neuroblastoma cells produce protease-resistant prion proteins. Journal of Virology, 62(5), 1558–1564.PubMedPubMedCentral

Cabantchik, Z. I., Munnich, A., Youdim, M. B., & Devos, D. (2013). Regional siderosis: A new challenge for iron chelation therapy. Frontiers in Pharmacology, 4(December), 167. doi:10.3389/fphar.2013.00167.PubMedPubMedCentral

Castellani, R. J., Siedlak, S. L., Perry, G., & Smith, M. A. (2000). Sequestration of iron by Lewy bodies in Parkinson’s disease. Acta Neuropathologica, 100(2), 111–114. doi:10.1007/s004010050001.CrossRefPubMed

Colvin, R. A., Bush, A. I., Volitakis, I., Fontaine, C. P., Thomas, D., Kikuchi, K., et al. (2008). Insights into Zn²⁺ homeostasis in neurons from experimental and modeling studies. American Journal of Physiology-Cell Physiology, 294, 726–742. doi:10.1152/ajpcell.00541.2007.CrossRef

Devos, D., Moreau, C., Devedjian, J. C., Kluza, J., Petrault, M., Laloux, C., et al. (2014). Targeting chelatable iron as a therapeutic modality in Parkinson’s disease. Antioxidants & Redox Signaling, 21(2), 195–210. doi:10.1089/ars.2013.5593.CrossRef

Dexter, D. T., Wells, F. R., Lees, A. J., Agid, F., Agid, Y., Jenner, P., et al. (1989). Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease. Journal of Neurochemistry, 52(6), 1830–1836. doi:10.1111/j.1471-4159.1989.tb07264.x.CrossRefPubMed

Elincx-Benizri, S., Glik, A., Merkel, D., Arad, M., Freimark, D., Kozlova, E., et al. (2016). Clinical experience with deferiprone treatment for Friedreich ataxia. Journal of Child Neurology, 31(8), 1036–1040. doi:10.1177/0883073816636087.CrossRefPubMed

Finkelstein, D. I., Hare, D. J., Billings, J. L., Sedjahtera, A., Nurjono, M., Arthofer, E., et al. (2016). Clioquinol improves cognitive, motor function, and microanatomy of the alpha-synuclein hA53T transgenic mice. ACS Chemical Neuroscience, 7(1), 119–129. doi:10.1021/acschemneuro.5b00253.CrossRefPubMed

Fredenburg, A. M., Sethi, R. K., Allen, D. D., & Yokel, R. A. (1996). The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethyl-, 1,2 diethyl-, and 1-[ethan-1-ol]-2-methyl-3-hydroxypyridin-4-one in the rat. Toxicology, 108(3), 191–199. doi:10.1016/0300-483X(95)03301-U.CrossRefPubMed

Fredriksson, A., Schröder, N., Eriksson, P., Izquierdo, I., & Archer, T. (1999). Neonatal iron exposure induces neurobehavioural dysfunctions in adult mice. Toxicology and Applied Pharmacology, 159(1), 25–30. doi:10.1006/taap.1999.8711.CrossRefPubMed

Funke, C., Schneider, S. A., Berg, D., & Kell, D. B. (2013). Genetics and iron in the systems biology of Parkinson’s disease and some related disorders. Neurochemistry International, 62(5), 637–652. doi:10.1016/j.neuint.2012.11.015.CrossRefPubMed

Galanello, R. (2007). Deferiprone in the treatment of transfusion-dependent thalassemia: A review and perspective. Therapeutics and Clinical Risk Management, 3(5), 795–805.PubMedPubMedCentral

Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002). Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron, 34(4), 521–533. doi:10.1016/S0896-6273(02)00682-7.CrossRefPubMed

Golts, N. (2002). Magnesium inhibits spontaneous and iron-induced aggregation of alpha -synuclein. Journal of Biological Chemistry, 277(18), 16116–16123. doi:10.1074/jbc.M107866200.CrossRefPubMed

Jones, B. J., & Roberts, D. J. (1968). The quantitative measurement of motor inco-ordination in naive mice using an accelerating rotarod. The Journal of Pharmacy and Pharmacology, 20(4), 302–304. doi:10.1111/j.2042-7158.1968.tb09743.x.CrossRefPubMed

Kalia, L. V., & Lang, A. E. (2015). Parkinson’s disease. Lancet (London, England), 386(9996), 896–912. doi:10.1016/S0140-6736(14)61393-3.CrossRef

Kasten, M., & Klein, C. (2013). The many faces of alpha-synuclein mutations. Movement Disorders, 28(6), 697–701. doi:10.1002/mds.25499.CrossRefPubMed

Kaur, D., Peng, J., Chinta, S. J., Rajagopalan, S., Di Monte, D. A., Cherny, R. A., et al. (2007). Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiology of Aging, 28(6), 907–913. doi:10.1016/j.neurobiolaging.2006.04.003.CrossRefPubMed

Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., et al. (2003). Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo. Neuron, 37(6), 899–909. doi:10.1016/S0896-6273(03)00126-0.CrossRefPubMed

Luk, K. C., Kehm, V. M., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M. Y. (2012). Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. The Journal of Experimental Medicine, 209(5), 975–986. doi:10.1084/jem.20112457.CrossRefPubMedPubMedCentral

Mao, X., & Schimmer, A. D. (2008). The toxicology of clioquinol. Toxicology Letters, 182(1–3), 1–6. doi:10.1016/j.toxlet.2008.08.015.CrossRefPubMed

Mutez, E., Nkiliza, A., Belarbi, K., de Broucker, A., Vanbesien-Mailliot, C., Bleuse, S., et al. (2014). Involvement of the immune system, endocytosis and EIF2 signaling in both genetically determined and sporadic forms of Parkinson’s disease. Neurobiology of Disease, 63, 165–170. doi:10.1016/j.nbd.2013.11.007.CrossRefPubMed

Oprandy, J. J., Olson, J. G., & Scott, T. W. (1988). A rapid dot immunoassay for the detection of serum antibodies to eastern equine encephalomyelitis and St. Louis encephalitis viruses in sentinel chickens. The American Journal of Tropical Medicine and Hygiene, 38(1), 181–186.CrossRefPubMed

Peng, Y., Wang, C., Xu, H. H., Liu, Y. N., & Zhou, F. (2010). Binding of α-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes. Journal of Inorganic Biochemistry, 104(4), 365–370. doi:10.1016/j.jinorgbio.2009.11.005.CrossRefPubMed

Perez, C., Tong, Y., & Guo, M. (2008). Iron chelators as potential therapeutic agents for Parkinson’s disease. Current Bioactive Compounds, 4(3), 150–158. doi:10.2174/157340708786305952.Iron.CrossRefPubMedPubMedCentral

Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science (New York, N.Y.), 276(5321), 2045–2047.CrossRef

Potter, K. A., Kern, M. J., Fullbright, G., Bielawski, J., Steven, S., Yum, S. W., et al. (2011). Central nervous system dysfunction in a mouse model of FA2H deficiency. Glia, 59(7), 1009–1021. doi:10.1002/glia.21172.Central.CrossRefPubMedPubMedCentral

Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014). The prevalence of Parkinson’s disease: A systematic review and meta-analysis. Movement Disorders, 29(13), 1583–1590. doi:10.1002/mds.25945.CrossRefPubMed

Saal, K.-A., Koch, J. C., Tatenhorst, L., Szegő, E. M., Ribas, V. T., Michel, U., et al. (2015). AAV. shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson’s disease in vitro and in vivo. Neurobiology of Disease, 73, 150–162. doi:10.1016/j.nbd.2014.09.013.CrossRefPubMed

Singleton, A. B., Farrer, M. J., & Bonifati, V. (2013). The genetics of Parkinson’s disease: progress and therapeutic implications. Movement Disorders : Official Journal of the Movement Disorder Society, 28(1), 14–23. doi:10.1002/mds.25249.CrossRef

Sohn, Y. S., Mitterstiller, A. M., Breuer, W., Weiss, G., & Cabantchik, Z. I. (2011). Rescuing iron-overloaded macrophages by conservative relocation of the accumulated metal. British Journal of Pharmacology, 164(2B), 406–418. doi:10.1111/j.1476-5381.2010.01120.x.CrossRefPubMedPubMedCentral

Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997). Alpha-synuclein in Lewy bodies. Nature, 388(6645), 839–840. doi:10.1038/42166.CrossRefPubMed

Sripetchwandee, J., Pipatpiboon, N., Chattipakorn, N., & Chattipakorn, S. (2014). Combined therapy of iron chelator and antioxidant completely restores brain dysfunction induced by iron toxicity. PLoS ONE, 9(1), 1–15. doi:10.1371/journal.pone.0085115.CrossRef

Tatenhorst, L., Eckermann, K., Dambeck, V., Fonseca-Ornelas, L., Walle, H., Lopes da Fonseca, T., et al. (2016). Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease. Acta Neuropathologica Communications, 4(1), 39. doi:10.1186/s40478-016-0310-y.CrossRefPubMedPubMedCentral

Tatenhorst, L., Tönges, L., Saal, K.-A., Koch, J. C., Szegő, E. M., Bähr, M., et al. (2014). Rho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of Parkinson disease. Journal of Neuropathology and Experimental Neurology, 73(8), 770–779. doi:10.1097/NEN.0000000000000095.CrossRefPubMed

Tönges, L., Frank, T., Tatenhorst, L., Saal, K. A., Koch, J. C., Szego, É. M., et al. (2012). Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson’s disease. Brain, 135, 3355–3370. doi:10.1093/brain/aws254.CrossRefPubMedPubMedCentral

Weinreb, O., Mandel, S., Youdim, M. B. H., & Amit, T. (2013). Targeting dysregulation of brain iron homeostasis in Parkinson’s disease by iron chelators. Free Radical Biology and Medicine, 62, 52–64. doi:10.1016/j.freeradbiomed.2013.01.017.CrossRefPubMed

Workman, D. G., Tsatsanis, A., Lewis, F. W., Boyle, J. P., Mousadoust, M., Hettiarachchi, N. T., et al. (2015). Protection from neurodegeneration in the 6-hydroxydopamine (6-OHDA) model of Parkinson’s with novel 1-hydroxypyridin-2-one metal chelators. Metallomics, 7, 867–876. doi:10.1039/C4MT00326H.CrossRefPubMed

Zhou, Z. D., Refai, F. S., Xie, S. P., Ng, S. H., Chan, C. H. S., Ho, P. G. H., et al. (2014). Mutant PINK1 upregulates tyrosine hydroxylase and dopamine levels, leading to vulnerability of dopaminergic neurons. Free Radical Biology and Medicine, 68, 220–233. doi:10.1016/j.freeradbiomed.2013.12.015.CrossRefPubMed

Title: Deferiprone Rescues Behavioral Deficits Induced by Mild Iron Exposure in a Mouse Model of Alpha-Synuclein Aggregation
Authors: Eleonora Carboni
Lars Tatenhorst
Lars Tönges
Elisabeth Barski
Vivian Dambeck
Mathias Bähr
Paul Lingor
Publication date: 01-09-2017
Publisher: Springer US
Published in: NeuroMolecular Medicine / Issue 2-3/2017
Print ISSN: 1535-1084
Electronic ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-017-8447-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Deferiprone Rescues Behavioral Deficits Induced by Mild Iron Exposure in a Mouse Model of Alpha-Synuclein Aggregation

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2-3/2017

Invaginating Presynaptic Terminals in Neuromuscular Junctions, Photoreceptor Terminals, and Other Synapses of Animals

Novel CD137 Gene Polymorphisms and Susceptibility to Ischemic Stroke in the Northern Chinese Han Population

Molecular Basis of Pediatric Brain Tumors

An Inframe Trinucleotide Deletion in MTRR Exon 1 is Associated with the Risk of Spina Bifida

Combination of EPA with Carotenoids and Polyphenol Synergistically Attenuated the Transformation of Microglia to M1 Phenotype Via Inhibition of NF-κB

Individual Amino Acid Supplementation Can Improve Energy Metabolism and Decrease ROS Production in Neuronal Cells Overexpressing Alpha-Synuclein